Compare LINK & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINK | MREO |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5M | 52.5M |
| IPO Year | 2007 | 2017 |
| Metric | LINK | MREO |
|---|---|---|
| Price | $5.48 | $0.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $8.67 | $1.50 |
| AVG Volume (30 Days) | 79.7K | ★ 1.8M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.83 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,890,000.00 | $500,000.00 |
| Revenue This Year | $43.26 | $5,184.20 |
| Revenue Next Year | $19.16 | $55.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $2.66 | $0.20 |
| 52 Week High | $15.15 | $2.94 |
| Indicator | LINK | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 79.57 | 67.99 |
| Support Level | $3.40 | $0.31 |
| Resistance Level | $10.55 | $0.36 |
| Average True Range (ATR) | 0.54 | 0.04 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 81.69 | 98.05 |
Interlink Electronics Inc is a sensor and printed electronics company operating in two principal sensor technology divisions: force/touch sensors, and gas and environmental sensors. It designs, develops, manufactures and sells a range of force-sensing and gas-sensing technologies that incorporate its proprietary materials technology, firmware and software into a portfolio of standard sensor-based products and custom sensor system solutions. Its force-sensing products and solutions include sensor components, subassemblies, modules products that support effective, efficient cursor control and novel three-dimensional user inputs. Its Human Machine Interface technology platforms are deployed in a wide range of markets including consumer electronics, automotive, industrial, and medical.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).